This company has been acquired
The company may no longer be operating, as it has been acquired. Find out why through their latest events.
Resumen acción MBII
Marrone Bio Innovations, Inc. discovers, develops, and sells biological products for crop protection, crop health, and crop nutrition.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Competidores de Marrone Bio Innovations, Inc.
Historial de precios y rendimiento
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.80 |
| 52 Week High | US$1.50 |
| 52 Week Low | US$0.55 |
| Beta | 0.36 |
| 1 Month Change | -26.10% |
| 3 Month Change | -18.58% |
| 1 Year Change | -43.40% |
| 3 Year Change | -43.80% |
| 5 Year Change | -27.45% |
| Change since IPO | -94.20% |
Noticias y actualizaciones recientes
Recent updates
Marrone Bio Innovations shareholders approve merger deal with Bioceres Crop Solutions
Jul 11Time To Worry? Analysts Are Downgrading Their Marrone Bio Innovations, Inc. (NASDAQ:MBII) Outlook
Aug 21
Marrone Bio Innovations, Inc. (NASDAQ:MBII) Is Expected To Breakeven In The Near Future
Apr 08Is Marrone Bio Innovations (NASDAQ:MBII) Using Too Much Debt?
Mar 13What Kind Of Investors Own Most Of Marrone Bio Innovations, Inc. (NASDAQ:MBII)?
Feb 15
Marrone Bio Innovations (NASDAQ:MBII) Shareholders Have Enjoyed A 75% Share Price Gain
Jan 25When Will Marrone Bio Innovations, Inc. (NASDAQ:MBII) Turn A Profit?
Jan 04Does Marrone Bio Innovations (NASDAQ:MBII) Have A Healthy Balance Sheet?
Dec 09Marrone Bio Innovations, Inc. 2020 Q3 - Results - Earnings Call Presentation
Nov 10Rentabilidad de los accionistas
| MBII | US Chemicals | Mercado US | |
|---|---|---|---|
| 7D | -19.6% | -2.3% | -0.9% |
| 1Y | -43.4% | 9.5% | 25.0% |
Rentabilidad frente al sector: MBII underperformed the US Chemicals industry which returned -12.9% over the past year.
Rentabilidad vs. Mercado: MBII underperformed the US Market which returned -19% over the past year.
Volatilidad de los precios
| MBII volatility | |
|---|---|
| MBII Average Weekly Movement | 13.9% |
| Chemicals Industry Average Movement | 5.2% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.0% |
Precio estable de las acciones: MBII's share price has been volatile over the past 3 months.
Volatilidad a lo largo del tiempo: MBII's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of US stocks.
Acerca de la empresa
| Fundada | Empleados | CEO | Página web |
|---|---|---|---|
| 2006 | 153 | Kevin Helash | www.marronebio.com |
Resumen de fundamentos de Marrone Bio Innovations, Inc.
| Estadísticas fundamentales de MBII | |
|---|---|
| Capitalización bursátil | US$145.56m |
| Beneficios(TTM) | -US$20.89m |
| Ingresos (TTM) | US$44.37m |
3.3x
Ratio precio-ventas (PS)-7.0x
Ratio precio-beneficio (PE)¿Está MBII sobrevalorada?
Ver valor justo y análisis de valoraciónBeneficios e Ingresos
| Cuenta de resultados (TTM) de MBII | |
|---|---|
| Ingresos | US$44.37m |
| Coste de los ingresos | US$17.89m |
| Beneficio bruto | US$26.48m |
| Otros gastos | US$47.37m |
| Beneficios | -US$20.89m |
Últimos beneficios comunicados
Mar 31, 2022
Próxima fecha de beneficios
n/a
| Beneficios por acción (BPA) | -0.11 |
| Margen bruto | 59.69% |
| Margen de beneficio neto | -47.08% |
| Ratio deuda/patrimonio | 139.3% |
¿Cómo se ha desempeñado MBII a largo plazo?
Ver rendimiento histórico y comparativa